DISCOVER TYVASO DPI

Skip to main content

For the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD; WHO Group 3) to improve exercise ability.

FOR US HEALTHCARE PROFESSIONALS ONLY

Skip to main content

IMPACT

PH significantly impacts patients with ILD1,2

PH in patients with ILD is associated with:

Increased need for supplemental oxygen2-4

Increased risk for acute exacerbations5

Decreased exercise capacity based on 6MWT and CPET3,6

Worsened prognosis1-4,7-9

PH is an increase in mean pulmonary arterial pressure (mPAP)2

Even mild increases in mPAP can impact patients with ILD (eg, IPF)3

About half of patients with both IPF and PH have slightly elevated mPAP of 25-30 mm Hg2

Limiting screening to severe PH may miss many patients with mild PH who have a worsened prognosis.

6MWT=6-minute walk test; CPET=cardiopulmonary exercise testing; ILD=interstitial lung disease; IPF=idiopathic pulmonary fibrosis; PH=pulmonary hypertension.